|
Download Complete Table of Contents 955k PDF
Table of Contents Synopsis:
Broad/Platform Technologies
- Cell-free systems
- Broad, cross- or multi-platform technologies
- Prokayotes
- Bacteria
- Yeasts
- Plants
- Eukaryotes
- Protozoa
- Animals, misc.
- Mammalian
- Chinese hamster ovary (CHO) cells
- Hybridomas
- Chickens/Poultry
- Human
- Insects
More Specific and Component Technologies
- Bacteria/Prokaryotes
- Yeasts
- Mammals
- Chinese hamster ovary (CHO) cells
- HEK-293 cells
- Plants
- Insects
Indexes
- Company/Organization Index
- Subject Index
- Primary Host/Organism Index
back to top
About the Author, Ronald A. Rader
Mr. Ronald A. Rader has a B.S. (Microbiology), an M.L.S. (Library Science), and over 25 years experience as a biotechnology and pharmaceutical information specialist, author and publisher. He is a world-class expert in biotechnology and pharmaceutical information, particularly competitive intelligence, technology and market assessments, and information resources development. Mr. Rader is the author of BIOPHARMA: Biopharmaceutical Products in the U.S. and European Markets, reference concerning biopharmaceuticals. He was also author of the Antiviral Agents Bulletin, the only periodical specializing in antiviral/HIV drug and vaccine development. He also published the Federal Bio-Technology Transfer Directory, abstracting all federal, e.g., NIH, inventions and technology transfers in biotech/biomedical areas, further marketed as an online database until 2000. Recent periodical articles include:
- "(Re)defining Biopharmaceutical" Nature Biotechnology, July 2008, 26(7), p. 743-751.
- "Expression Systems for Process and Product Development: A Perspective on Opportunities for Innovator and Follow-on Product Developers," BioProcess International, vol. 6, issue 6, suppl. 4, Success Stories in Protein Expression (lead article), p. 4-9, June 2008.
- "Biopharmaceuticals: Lack of Information Disclosure Confounds Public Trust, Particularly in the Context of Biosimilars," BioWorld Perspectives, vol. 2, issue 18, May 1, 2008.
- "Paucity of Biopharma Approvals Raises Alarm: Lower Numbers, Novelty and Economic Impact Indicate Problems," Genetic Engineering & Biotechnology News (GEN), March 15, 2008
- "How Big is the World Market for Biopharmaceuticals? It All Depends How You Define Biopharmaceutical," in Friedman, Y., Best Practices in Biotechnology Business Development, Logo Press, p. 175-85, 2008.
- "What Is a Generic Biopharmaceutical? Biogeneric? Follow-On Protein? Biosimilar? Follow-On Biologic?" Part 1: Introduction and Basic Paradigms - BioProcess International, March 2007.
- "What Is a Generic Biopharmaceutical? Biogeneric? Follow-On Protein? Biosimilar? Follow-On Biologic?" Part 2: Information, Nomenclature, Perceptions, and the Market - BioProcess International, May 2007.
- Biopharmaceutical Approvals Review - Genetic Engineering News, Aug. 1, 2006
- What is a Biopharmaceutical, Part 1: (Bio)Technology-Based Definitions - BioExecutive, March 2005.
- What is a Biopharmaceutical, Part 2: Company and Industry Definitions - BioExecutive, May 2005.
E-mail
BioPlan Associates to contact the author or obtain additional information |
